Market revenue in 2023 | USD 1,413.2 million |
Market revenue in 2030 | USD 0.0 million |
Growth rate | -100% (CAGR from 2023 to 2030) |
Largest segment | Gene therapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
Key market players worldwide | Bluebird bio Inc, Novartis AG ADR, UniQure NV, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Vericel Corp, Organogenesis Holdings Inc Class A, Spark Therapeutics, Celgene, Kolon Industries, Medipost, Pharmicell |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 52% in 2023. Horizon Databook has segmented the Europe advanced therapy medicinal products market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2030.
Although the number of ATMP developers is significantly lower in this region than North America, Europe accounts for a major share in the number of ongoing clinical trials. Moreover, clinical development activity continues to increase in the region.
The EMA has played a crucial role in proliferation of pipeline candidates. Furthermore, emergence of CMO-based business model is expected to further boost revenue growth. The UK has dominated in CMO services market within this region.
Europe is the second-largest pharmaceutical market globally, with Western Europe accounting for a large proportion of drug revenue. In the coming years, cell therapy developers are anticipated to account for a major share of Europe’s drug revenues.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe advanced therapy medicinal products market , including forecasts for subscribers. This continent databook contains high-level insights into Europe advanced therapy medicinal products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account